{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:47:57Z","timestamp":1784000877088,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2300603"],"award-info":[{"award-number":["2021YFC2300603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972694"],"award-info":[{"award-number":["81972694"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05917-x","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T12:36:52Z","timestamp":1734698212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Napabucasin-loaded PLGA nanoparticles trigger anti-HCC immune responses by metabolic reprogramming of tumor-associated macrophages"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhenwei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-1397","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"1","key":"5917_CR1","first-page":"261","volume":"13","author":"Z Fan","year":"2023","unstructured":"Fan Z, Zhou P, Jin B, Li G, Feng L, Zhuang C, Wang S. Recent therapeutics in hepatocellular carcinoma. Am J Cancer Res. 2023;13(1):261\u201375.","journal-title":"Am J Cancer Res"},{"issue":"10126","key":"5917_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"2","key":"5917_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"TF Greten","year":"2019","unstructured":"Greten TF, Lai CW, Li G, Staveley-O\u2019Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156(2):510\u201324.","journal-title":"Gastroenterology"},{"issue":"11","key":"5917_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3390\/cancers11111646","volume":"11","author":"C Lee","year":"2019","unstructured":"Lee C, Cheung ST. STAT3: an emerging therapeutic target for hepatocellular carcinoma. Cancers. 2019;11(11):1646.","journal-title":"Cancers"},{"issue":"5","key":"5917_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309\u201324.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"5917_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J. NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4(3):176\u201385.","journal-title":"Protein Cell"},{"issue":"1","key":"5917_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-019-0993-3","volume":"18","author":"S Jin","year":"2019","unstructured":"Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2\/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer. 2019;18(1):38.","journal-title":"Mol Cancer"},{"key":"5917_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2019.10.005","volume":"49","author":"L Yang","year":"2019","unstructured":"Yang L, Lin S, Xu L, Lin J, Zhao C, Huang X. Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine Growth Factor Rev. 2019;49:10\u201322.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"5917_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","volume":"3","author":"DJ Jonker","year":"2018","unstructured":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(4):263\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5917_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.597520","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin reduces cancer stem cell characteristics in hepatocellular carcinoma. Front Pharmacol. 2020;11: 597520.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5917_CR11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Y Su","year":"2021","unstructured":"Su Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, Wang R, Chen C. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021;28(1):1397\u2013418.","journal-title":"Drug Deliv"},{"issue":"2","key":"5917_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13346-017-0377-4","volume":"8","author":"AE Grill","year":"2018","unstructured":"Grill AE, Shahani K, Koniar B, Panyam J. Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer. Drug Deliv Transl Res. 2018;8(2):329\u201341.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"5917_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/10717544.2017.1422296","volume":"25","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Wang X, Li B, Hou Y, Yang J, Yi L. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations. Drug Deliv. 2018;25(1):166\u201377.","journal-title":"Drug Deliv"},{"issue":"4","key":"5917_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1021\/acs.molpharmaceut.8b00959","volume":"16","author":"SR Shah","year":"2019","unstructured":"Shah SR, Kim J, Schiapparelli P, Vazquez-Ramos CA, Martinez-Gutierrez JC, Ruiz-Valls A, Inman K, Shamul JG, Green JJ, Quinones-Hinojosa A. Verteporfin-loaded polymeric microparticles for intratumoral treatment of brain cancer. Mol Pharm. 2019;16(4):1433\u201343.","journal-title":"Mol Pharm"},{"issue":"6","key":"5917_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"key":"5917_CR16","doi-asserted-by":"crossref","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084.","DOI":"10.3389\/fimmu.2020.583084"},{"issue":"3","key":"5917_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7150\/thno.51777","volume":"11","author":"D Chen","year":"2021","unstructured":"Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016\u201330.","journal-title":"Theranostics"},{"issue":"6","key":"5917_CR18","first-page":"1533","volume":"26","author":"Y Fujiwara","year":"2011","unstructured":"Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T, Takeya M. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol Rep. 2011;26(6):1533\u20137.","journal-title":"Oncol Rep"},{"key":"5917_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2022.129723","volume":"651","author":"V Mohammadzadeh","year":"2022","unstructured":"Mohammadzadeh V, Norouzi A, Ghorbani M. Multifunctional nanocomposite based on lactose@layered double hydroxide-hydroxyapatite as a pH-sensitive system for targeted delivery of doxorubicin to liver cancer cells. Colloids Surf A. 2022;651: 129723.","journal-title":"Colloids Surf A"},{"issue":"8","key":"5917_CR20","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1021\/mp400154a","volume":"10","author":"S Modi","year":"2013","unstructured":"Modi S, Anderson BD. Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method. Mol Pharm. 2013;10(8):3076\u201389.","journal-title":"Mol Pharm"},{"issue":"10","key":"5917_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40265-017-0759-4","volume":"77","author":"JM Hubbard","year":"2017","unstructured":"Hubbard JM, Grothey A. Napabucasin: an update on the first-in-class cancer stemness inhibitor. Drugs. 2017;77(10):1091\u2013103.","journal-title":"Drugs"},{"issue":"3","key":"5917_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","volume":"6","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670\u201390.","journal-title":"Cancers"},{"issue":"12","key":"5917_CR23","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/cancers11121832","volume":"11","author":"G Verdeil","year":"2019","unstructured":"Verdeil G, Lawrence T, Schmitt-Verhulst AM, Auphan-Anezin N. Targeting STAT3 and STAT5 in tumor-associated immune cells to improve immunotherapy. Cancers. 2019;11(12):1832.","journal-title":"Cancers"},{"issue":"7","key":"5917_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Wenes M, Romero P, Huang SC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16(7):425\u201341.","journal-title":"Nat Rev Clin Oncol"},{"key":"5917_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2018.01.020","volume":"330","author":"A Remmerie","year":"2018","unstructured":"Remmerie A, Scott CL. Macrophages and lipid metabolism. Cell Immunol. 2018;330:27\u201342.","journal-title":"Cell Immunol"},{"issue":"9","key":"5917_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","volume":"55","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina. 2019;55(9):526.","journal-title":"Medicina"},{"issue":"17","key":"5917_CR27","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.4161\/cc.9.17.12946","volume":"9","author":"Y Liu","year":"2010","unstructured":"Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle. 2010;9(17):3423\u20137.","journal-title":"Cell Cycle"},{"issue":"3","key":"5917_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccr.2009.12.048","volume":"17","author":"G He","year":"2010","unstructured":"He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. Hepatocyte IKKbeta\/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17(3):286\u201397.","journal-title":"Cancer Cell"},{"issue":"1","key":"5917_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","volume":"21","author":"G He","year":"2011","unstructured":"He G, Karin M. NF-\u03baB and STAT3\u2014key players in liver inflammation and cancer. Cell Res. 2011;21(1):159\u201368.","journal-title":"Cell Res"},{"key":"5917_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105169","volume":"115","author":"Z Wang","year":"2021","unstructured":"Wang Z, Hui C, Xie Y. Natural STAT3 inhibitors: a mini perspective. Bioorg Chem. 2021;115: 105169.","journal-title":"Bioorg Chem"},{"issue":"6","key":"5917_CR31","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1073\/pnas.1424171112","volume":"112","author":"Y Li","year":"2015","unstructured":"Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB, Li CJ. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA. 2015;112(6):1839\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"5917_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","volume":"8","author":"OMT Pearce","year":"2018","unstructured":"Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, B\u00f6hm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 2018;8(3):304\u201319.","journal-title":"Cancer Discov"},{"issue":"5","key":"5917_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293-1308.e1236.","journal-title":"Cell"},{"issue":"4","key":"5917_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17(4):251\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"34","key":"5917_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803322","volume":"31","author":"H Phuengkham","year":"2019","unstructured":"Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. Adv Mater. 2019;31(34): e1803322.","journal-title":"Adv Mater"},{"issue":"12","key":"5917_CR36","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm1325","volume":"11","author":"M Kortylewski","year":"2005","unstructured":"Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mul\u00e9 J, Kerr WG, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314\u201321.","journal-title":"Nat Med"},{"issue":"19","key":"5917_CR37","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","volume":"70","author":"A Herrmann","year":"2010","unstructured":"Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010;70(19):7455\u201364.","journal-title":"Cancer Res"},{"issue":"15","key":"5917_CR38","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2014-03-564450","volume":"124","author":"D Gotthardt","year":"2014","unstructured":"Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, M\u00fcller M, Sexl V. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014;124(15):2370\u20139.","journal-title":"Blood"},{"issue":"9","key":"5917_CR39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41423-023-01061-6","volume":"20","author":"M Bied","year":"2023","unstructured":"Bied M, Ho WW, Ginhoux F, Bl\u00e9riot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20(9):983\u201392.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"5917_CR40","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.cmet.2021.07.017","volume":"33","author":"SA Eming","year":"2021","unstructured":"Eming SA, Murray PJ, Pearce EJ. Metabolic orchestration of the wound healing response. Cell Metab. 2021;33(9):1726\u201343.","journal-title":"Cell Metab"},{"key":"5917_CR41","doi-asserted-by":"publisher","first-page":"9029327","DOI":"10.1155\/2017\/9029327","volume":"2017","author":"T Wang","year":"2017","unstructured":"Wang T, Liu H, Lian G, Zhang SY, Wang X, Jiang C. HIF1\u03b1-induced glycolysis metabolism is essential to the activation of inflammatory macrophages. Mediat Inflamm. 2017;2017:9029327.","journal-title":"Mediat Inflamm"},{"issue":"15","key":"5917_CR42","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/1878-0261.13263","volume":"16","author":"Y Li","year":"2022","unstructured":"Li Y, Song Z, Han Q, Zhao H, Pan Z, Lei Z, Zhang J. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis. Mol Oncol. 2022;16(15):2861\u201380.","journal-title":"Mol Oncol"},{"key":"5917_CR43","doi-asserted-by":"crossref","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b\/\u03b2-catenin\/c-Myc signaling and reprogramming glycolysis. J Exp Clin Cancer Res. 2021;40(1):13.","DOI":"10.1186\/s13046-020-01808-3"},{"key":"5917_CR44","doi-asserted-by":"crossref","unstructured":"Van den Bossche J, O'Neill LA, Menon D. Macrophage immunometabolism: where are we (going)? Trends Immunol. 2017;38(6):395\u2013406.","DOI":"10.1016\/j.it.2017.03.001"},{"issue":"3","key":"5917_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00262-019-02301-3","volume":"68","author":"MN Andersen","year":"2019","unstructured":"Andersen MN, Etzerodt A, Graversen JH, Holthof LC, Moestrup SK, Hokland M, M\u00f8ller HJ. STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes. Cancer Immunol Immunother. 2019;68(3):489\u2013502.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"5917_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","volume":"15","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, Paulos CM. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458\u201369.","journal-title":"Cell Mol Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05917-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:04:36Z","timestamp":1734699876000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05917-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5917"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05917-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal protocols and experiments were approved by the Institutional Animal Care and Use Committee of Shandong University, China, and complied with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All contributing authors agreed to the publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1125"}}